Background Preliminary reports of studies involving simple coronary lesions indicate that a
sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous …

Objectives: The purpose of this study was to examine the two-year clinical outcomes in
patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions …

Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy
outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native …

Background—Sirolimus-eluting stents (SESs) reduce angiographic restenosis in patients
with focal, native coronary artery stenoses. This study evaluated the usefulness of SESs in …

ContextPercutaneous coronary revascularization of small vessels is associated with a high
restenosis rate. Sirolimus-eluting stents reduce restenosis in simple and previously …

Background The need for repeated treatment of restenosis of a treated vessel remains the
main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) …

Background—Recently, sirolimus-eluting stents (SESs) have been shown to dramatically
reduce the risk of angiographic and clinical restenosis compared with bare metal stent …

Background—The use of sirolimus-eluting coronary stents has been associated with a
nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence …

Background—This study evaluated a large group of patients enrolled in a double-blind
randomized trial of the sirolimus-eluting stent to document whether the initial clinical …

Objectives: This study examined the clinical outcomes at 5 years in RAVEL (A Randomized
Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary …